ARS Pharmaceuticals, Inc. SPRY Debt-to-assets
Debt-to-assets at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s debt-to-assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s debt-to-assets?
- ARS Pharmaceuticals, Inc. (SPRY) reported debt-to-assets of 0.3× in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s debt-to-assets changed year-over-year?
- ARS Pharmaceuticals, Inc.'s debt-to-assets increased by 167700.0% year-over-year, from 0× to 0.3×.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s debt-to-assets?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s debt-to-assets has grown at a 104.6% compound annual growth rate (CAGR), from 0× to 0.3×.
- What does debt-to-assets mean?
- Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.